BioAffinity Technologies Inc(BIAF) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -103.29 | Insider Own | 0.82% | Shs Outstand | 1.3M | Perf Week | -12.04% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 1.3M | Perf Month | -54.36% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 4.59% | Short Float | 5.25% | Perf Quarter | -67.52% |
| Income | -0.02B | P/S | 0.68 | EPS this Y | - | Inst Trans | 6.51% | Short Ratio | 0.02 | Perf Half Y | -91.39% |
| Sales | 0.01B | P/B | 0.38 | EPS next 5Y | - | ROA | -245.51% | Short Interest | 0.07M | Perf YTD | -82.26% |
| Book/sh | 8.33 | P/C | 1.66 | EPS past 3/5Y | 45.79% 21.77% | ROE | -1860.15% | 52W High | -96.11% ($80.70) | Perf Year | -91.59% |
| Cash/sh | 1.89 | P/FCF | - | Sales past 3/5Y | 986.6% - | ROIC | -307.49% | 52W Low | 18.05% ($2.66) | Perf 3Y | -99.48% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 67.18% | Gross Margin | 27.61% | Volatility(W/M) | 13.82% 14.67% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 0.52 | Sales Y/Y TTM | -23.17% | Oper. Margin | -209.82% | ATR (14) | 0.83 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.41 | EPS Q/Q | 87.3% | Profit Margin | -257.33% | RSI (14) | 35.46 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.44 | Sales Q/Q | 18.99% | SMA20 | -26.46% ($4.27) | Beta | -1.2 | Target Price | $2700 |
| Payout | - | Debt/Eq | 0.38 | Earnings | 2026/8/7 | SMA50 | -49.98% ($6.28) | Rel Volume | 0.02 | Prev Close | $2.96 |
| Employees | 57 | LT Debt/Eq | 0.31 | EPS/Sales Surpr. | - | SMA200 | -83.82% ($19.41) | Avg Volume(3M) | 3.66M | Price | $3.14 |
| IPO | 2022/9/1 | Option/Short | No/Yes | Trades | 428 | Volume | 55,809 | Change | 6.08% |
CyPath® Lung is a small in-vitro diagnostics company that develops and sells a diagnostic platform, "CyPath® Lung," for the non-invasive early detection of lung cancer using sputum (expectorated phlegm). By combining flow cytometry with proprietary AI, the company is commercializing the platform as an adjunct tool to help determine whether patients with indeterminate nodules found on lung CT scans should undergo additional invasive testing.
Over the past 1 year, on the lower side
96% below its 1-year high.
Traded less than usual. That is 2% of its average volume.
BIAF has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $68. Peers typically go for $458.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -99.5%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 4.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
DFAS U.S. Small Cap Portfolio-ETF Class Shares <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #43 of 44 in the industry
Based on market cap of $4M.
XWEL#40 XWELL Inc $7M PER - 
NDRA#41 ENDRA Life Sciences Inc $7M PER - 
ADVB#42 Advanced Biomed Inc $5M PER - BIAF#43 BioAffinity Technologies Inc $4M PER - 
ISPC#44 iSpecimen Inc $2M PER - 
FAQ
What kind of company is BIAF?
BIAF belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of BIAF?
The market cap of BIAF is approximately $4M, ranking 5,674 within its sector.
What is the 52-week high and low for BIAF?
BIAF has recorded a 52-week high of $80.70 and a low of $2.66.
